



11-30-05

ZFW

CASE 4-31617B

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 704617659 US  
Express Mail Label NumberNovember 29, 2005  
Date of Deposit

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1635

LIAU ET AL. \*

APPLICATION NO: 10/619,344

FILED: JULY 14, 2003


FOR: INTRODUCTION OF BLOOD VESSEL FORMATION THROUGH  
ADMINISTRATION OF POLYNUCLEOTIDES ENCODING  
SPHINGOSINE KINASES**MS: Amendment**Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement of November 15, 2005, Applicant elects the claims of Group 2, claims 2-14, 23-28 and 33-39, drawn to methods expressing protein, inducing blood vessel formation in an animal by administering a polynucleotide encoding sphingosine kinase. This election is made without traverse.

Regarding the species of angiogenic factors listed in claims 4 and 35, Applicants select FGF as the species of angiogenic factor.

The due date for response to this Restriction Requirement is December 15, 2005. Accordingly, this election is timely made.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(617) 871-3346  
John T. Prince  
Attorney for Applicants  
Reg. No. 43,019

Date: November 29, 2005